SG10201906842WA - Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections - Google Patents

Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections

Info

Publication number
SG10201906842WA
SG10201906842WA SG10201906842WA SG10201906842WA SG10201906842WA SG 10201906842W A SG10201906842W A SG 10201906842WA SG 10201906842W A SG10201906842W A SG 10201906842WA SG 10201906842W A SG10201906842W A SG 10201906842WA SG 10201906842W A SG10201906842W A SG 10201906842WA
Authority
SG
Singapore
Prior art keywords
bacterial infections
fused
treatment
heteroaromatic compounds
spirocyclic
Prior art date
Application number
SG10201906842WA
Inventor
Michael Huband
Original Assignee
Entasis Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics Ltd filed Critical Entasis Therapeutics Ltd
Publication of SG10201906842WA publication Critical patent/SG10201906842WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS Disclosed are methods for treating various bacterial infections with (2R,4S,4aS)-11-fluoro-2,4- dimethyl-8-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4a-tetrahydro-2'H,6H-spiro[1,4- oxazino[4,3-a][1,2]oxazolo[4,5-g]quinoline-5,5'-pyrimidine]-2',4',6' (1'H,3'H)-trione, or a pharmaceutically acceptable salt thereof. [No Figure]
SG10201906842WA 2014-05-29 2015-05-27 Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections SG10201906842WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462004246P 2014-05-29 2014-05-29

Publications (1)

Publication Number Publication Date
SG10201906842WA true SG10201906842WA (en) 2019-08-27

Family

ID=54329851

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201906842WA SG10201906842WA (en) 2014-05-29 2015-05-27 Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
SG11201609404SA SG11201609404SA (en) 2014-05-29 2015-05-27 Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201609404SA SG11201609404SA (en) 2014-05-29 2015-05-27 Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections

Country Status (14)

Country Link
US (1) US10238661B2 (en)
EP (1) EP3148546A1 (en)
JP (1) JP6502387B6 (en)
KR (1) KR20170007818A (en)
CN (1) CN106659725A (en)
AU (1) AU2015265620B2 (en)
CA (1) CA2948438A1 (en)
EA (1) EA033459B1 (en)
IL (1) IL248838B (en)
MX (1) MX365261B (en)
PH (1) PH12016502271B1 (en)
SG (2) SG10201906842WA (en)
TW (1) TWI657818B (en)
WO (1) WO2015181637A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109111465B (en) 2017-06-22 2021-01-12 中国科学院上海药物研究所 Thiazolidone spiropyrimidine trione compound and preparation method and application thereof
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208490B2 (en) * 2002-10-07 2007-04-24 Pharmacia & Upjohn Company Llc Tricyclic tetrahydroquinoline antibacterial agents
DE602004019548D1 (en) 2003-08-15 2009-04-02 Astrazeneca Ab CONDENSED HETEROCYCLES AS INHIBITORS OF GLUTAMATRACEMASE (MURI)
JP2008543739A (en) 2005-05-09 2008-12-04 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Antibacterial agent
DOP2006000268A (en) 2005-12-22 2007-07-31 Pfizer Prod Inc ANTIBACTERIAL AGENTS
CL2007003332A1 (en) 2006-11-24 2008-06-20 Actelion Pharmaceuticals Ltd COMPOUNDS DERIVED FROM CONDENSED HETEROCICLES; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE PREVENTION OR TREATMENT OF BACTERIAL INFECTIONS.
CN101784553A (en) 2007-07-02 2010-07-21 阿斯利康(瑞典)有限公司 3-spiropyrimidinetrione-quinoline derivatives and their use as antibacterial agents
JP5749169B2 (en) * 2008-10-14 2015-07-15 アストラゼネカ アクチボラグ Fused spirocyclic heteroaromatic compounds for the treatment of bacterial infections
US9040528B2 (en) 2008-10-14 2015-05-26 Astrazeneca Ab Chemical compounds 542
AR084070A1 (en) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc BROMODOMINIUM INHIBITORS AND USES OF THE SAME
US8952149B2 (en) 2012-09-26 2015-02-10 Zoetis Llc Tricyclic tetrahydroquinoline antibacterial agents
US8889671B2 (en) 2013-01-23 2014-11-18 Astrazeneca Ab Compounds and methods for treating bacterial infections

Also Published As

Publication number Publication date
JP6502387B6 (en) 2019-05-29
IL248838B (en) 2020-05-31
WO2015181637A1 (en) 2015-12-03
CA2948438A1 (en) 2015-12-03
MX365261B (en) 2019-05-27
MX2016015632A (en) 2017-04-25
AU2015265620A1 (en) 2016-11-24
IL248838A0 (en) 2017-01-31
EA201692250A1 (en) 2017-06-30
PH12016502271A1 (en) 2017-02-06
SG11201609404SA (en) 2016-12-29
EA033459B1 (en) 2019-10-31
US10238661B2 (en) 2019-03-26
JP6502387B2 (en) 2019-04-17
JP2017516777A (en) 2017-06-22
AU2015265620B2 (en) 2020-04-09
TWI657818B (en) 2019-05-01
US20180169104A1 (en) 2018-06-21
TW201607537A (en) 2016-03-01
KR20170007818A (en) 2017-01-20
EP3148546A1 (en) 2017-04-05
PH12016502271B1 (en) 2017-02-06
CN106659725A (en) 2017-05-10

Similar Documents

Publication Publication Date Title
IL251285A0 (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
PL3838274T3 (en) Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivative for use in the treatment of cns disorders
SG10201902598VA (en) Peptidomimetic macrocycles and formulations thereof
WO2015112806A3 (en) Diaryl macrocycles as modulators of protein kinases
LT3183254T (en) New spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
NZ763737A (en) 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
PH12019501079A1 (en) Magl inhibitors
PH12016502307A1 (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
TW201613935A (en) Tricyclic heterocycles as BET protein inhibitors
WO2016098054A9 (en) Processes for preparing oxathiazin-like compounds
MX2016015762A (en) Alkyl and aryl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain.
MX2016015761A (en) Amide derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain.
ZA201700110B (en) Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction
PH12016502271B1 (en) Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
EP3626727A4 (en) Compound, synthetic intermediate, use, pharmaceutical composition, and neuromodulatory therapeutic method
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
MX2018014034A (en) Fused bicyclic compounds for the treatment of disease.
BR112018016208A2 (en) heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their uses as antibacterial compounds
CA3011077A1 (en) Pharmaceutical formulations and their use for the treatment of retinitis pigmentosa
EP3191441A4 (en) Novel process for preparation of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione
IL265985A (en) Process for the preparation of (3s,4s)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3h-imidazo[4,5-c]pyridine-5(4h)-carboxylate
ZA201705052B (en) Novel combination of 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione with an antidepressant, and the pharmaceutical compositions containing same